[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
[HTML][HTML] Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
The isolation and analysis of circulating cell-free tumor DNA in plasma is a powerful tool with
considerable potential to improve clinical outcomes across multiple cancer types, including …
considerable potential to improve clinical outcomes across multiple cancer types, including …
Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer
JT Zhang, SY Liu, W Gao, SYM Liu, HH Yan, L Ji… - Cancer Discovery, 2022 - AACR
The efficacy and potential limitations of molecular residual disease (MRD) detection urgently
need to be fully elucidated in a larger population of non–small cell lung cancer (NSCLC) …
need to be fully elucidated in a larger population of non–small cell lung cancer (NSCLC) …
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
Y Nakamura, H Taniguchi, M Ikeda, H Bando, K Kato… - Nature medicine, 2020 - nature.com
Comprehensive genomic profiling enables genomic biomarker detection in advanced solid
tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we …
tumors. Here, to evaluate the utility of circulating tumor DNA (ctDNA) genotyping, we …
Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor …
R Woodhouse, M Li, J Hughes, D Delfosse… - PloS one, 2020 - journals.plos.org
As availability of precision therapies expands, a well-validated circulating cell-free DNA
(cfDNA)-based comprehensive genomic profiling assay has the potential to provide …
(cfDNA)-based comprehensive genomic profiling assay has the potential to provide …
Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer
C Aggarwal, JC Thompson, TA Black, SI Katz… - JAMA …, 2019 - jamanetwork.com
Importance The clinical implications of adding plasma-based circulating tumor DNA next-
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
generation sequencing (NGS) to tissue NGS for targetable mutation detection in non–small …
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA
(cfDNA) requires understanding of the various biological compartments contributing to the …
(cfDNA) requires understanding of the various biological compartments contributing to the …
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
SS Ramalingam, JCH Yang, CK Lee… - Journal of Clinical …, 2018 - ascopubs.org
Purpose The AURA study (ClinicalTrials. gov identifier: NCT01802632) included two cohorts
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
of treatment-naïve patients to examine clinical activity and safety of osimertinib (an …
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR …
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR …
Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients
Y Zhang, Y Yao, Y Xu, L Li, Y Gong, K Zhang… - Nature …, 2021 - nature.com
Circulating tumor DNA (ctDNA) provides a noninvasive approach to elucidate a patient's
genomic landscape and actionable information. Here, we design a ctDNA-based study of …
genomic landscape and actionable information. Here, we design a ctDNA-based study of …